3SPA.PA falls 6.87% on 06 Jan 2026 EURONEXT close: watch liquidity risks
GraniteShares 3x Short Palantir (3SPA.PA stock) fell 6.87% to €0.01 at the EURONEXT close on 06 Jan 2026. Trading volume accelerated to 21,930,626.00 shares, above the average of 18,852,795.00. The movement left the leveraged ETC near its year low and raised liquidity questions for short-exposure holders.
Price action and market context for 3SPA.PA stock
3SPA.PA opened at €0.01 and traded between €0.01 and €0.01 on the day. The intraday range was tight but the session ended with a -6.87% move versus the previous close of €0.01. Volume at 21,930,626.00 implies traders rebalanced leveraged positions on Palantir moves.
Why 3SPA.PA lost ground today: catalysts and news
The ETC mirrors short, leveraged exposure to PLTR and tracks daily rebalancing. Weakness in underlying Palantir flows and rebalancing pressure can rapidly push the ETC lower. Market discussion and price updates were reported by Yahoo Finance, suggesting higher short-covering and reweighting activity across listings Yahoo Finance 3SPA.PA.
3SPA.PA stock technical snapshot and ratios
Technicals show a low RSI at 33.09, hinting near oversold conditions. Price averages diverge sharply, with 50-day avg €0.49 and 200-day avg €9.56, reflecting a collapse from issuance levels. Market cap reads €720.00 and shares outstanding are 58,988.00, highlighting tiny residual value relative to initial listing.
Meyka AI rates 3SPA.PA with a score out of 100
Meyka AI rates 3SPA.PA with a score of 67.55 / 100, grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Grades are informational and not financial advice.
Meyka AI’s forecast and price target for 3SPA.PA stock
Meyka AI’s forecast model projects €0.0060 in three months versus current price €0.0122, implying -50.82% downside. Forecasts are model-based projections and not guarantees. Use this alongside liquidity checks and stop levels when sizing positions.
Fund structure, sector context and trading risks
The product sits in Asset Management – Leveraged within Financial Services on EURONEXT in Europe. As a -3x daily ETC, 3SPA.PA amplifies daily moves and suffers path dependency. Key risks are compaction toward zero, high volatility, and low NAV. Sector trends show healthier breadth in Financial Services, but leveraged products carry unique risks. For cross-listing data and ticker comparisons see Yahoo Finance 3SPA.L and our Meyka page for the ticker.
Final Thoughts
3SPA.PA stock closed lower at €0.01 on EURONEXT on 06 Jan 2026 after a -6.87% session. The ETC’s tiny market cap of €720.00 and elevated turnover show stressed liquidity and concentrated trading. Technicals lean oversold while daily rebalancing mechanics raise path risk for multi-day holders. Meyka AI’s model projects €0.0060 in three months from the current €0.0122, an implied downside of -50.82%. Forecasts are model-based projections and not guarantees. Investors should treat 3SPA.PA as a tactical, high-risk trading vehicle and check liquidity, intraday spreads, and position sizing before trading. Meyka AI provides AI-powered market analysis and tools to monitor leveraged ETC flows.
FAQs
The decline stems from daily rebalancing of the -3x short exposure to PLTR, higher trading volume, and limited liquidity. These forces amplify moves and can drive sharp intraday falls in 3SPA.PA stock.
Meyka AI’s model forecasts **€0.0060** in three months versus the current **€0.0122**, implying downside. This projection is model-based and not a guarantee; monitor liquidity and underlying PLTR trends.
No. 3SPA.PA is a daily leveraged ETC designed for short-term tactical trades. Path dependency and decay make it unsuitable for buy-and-hold investors seeking steady returns.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.